{"filing":{"accession_number":"0001104659-26-111654","cik":"0001590560","ticker":"QURE","company_name":"uniQure N.V.","form":"8-K","filing_date":"2026-09-29","report_date":"2026-09-29","primary_document":"tm2626514d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1590560/000110465926111654/tm2626514d1_8k.htm"},"events":[{"id":35650,"run_id":32846,"accession_number":"0001104659-26-111654","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"uniQure disclosed an update on its ongoing Phase I/II clinical trials of AMT-130 for Huntington's Disease, presenting 48-month efficacy and safety data. The presentation and press release detail statistically significant slowing of disease progression at 36 and 48 months, dose-dependent responses, and continued tolerability. This is a material clinical development milestone for a gene therapy candidate in active development, affecting investor assessment of the company's pipeline and regulatory pathway prospects, but does not constitute a formal earnings release, M\u0026A activity, or other specifically-named event type.","company_name":"uniQure N.V.","ticker":"QURE","filing_date":"2026-09-29","form":"8-K","submitted_at":null,"items":[{"id":39790,"accession_number":"0001104659-26-111654","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"uniQure disclosed an update on its ongoing Phase I/II clinical trials of AMT-130 for Huntington's Disease, presenting 48-month efficacy and safety data. The presentation and press release detail statistically significant slowing of disease progression at 36 and 48 months, dose-dependent responses, and continued tolerability. This is a material clinical development milestone for a gene therapy candidate in active development, affecting investor assessment of the company's pipeline and regulatory pathway prospects, but does not constitute a formal earnings release, M\u0026A activity, or other specifically-named event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T13:06:39.176925+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":39790,"accession_number":"0001104659-26-111654","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"uniQure disclosed an update on its ongoing Phase I/II clinical trials of AMT-130 for Huntington's Disease, presenting 48-month efficacy and safety data. The presentation and press release detail statistically significant slowing of disease progression at 36 and 48 months, dose-dependent responses, and continued tolerability. This is a material clinical development milestone for a gene therapy candidate in active development, affecting investor assessment of the company's pipeline and regulatory pathway prospects, but does not constitute a formal earnings release, M\u0026A activity, or other specifically-named event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-29T13:06:39.176925+00:00","company_name":"uniQure N.V.","ticker":"QURE","filing_date":"2026-09-29"}]}